{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:32:38Z","timestamp":1773131558386,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2013\/08216-2"],"award-info":[{"award-number":["2013\/08216-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["425075\/2016-8"],"award-info":[{"award-number":["425075\/2016-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>In chronic arthropathies, there are several mechanisms of joint destruction. In recent years, studies have reported the implication of receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) in the process of activation and differentiation of osteoclasts, a key cell in the development of bone erosion. The RANKL\/OPG ratio is increased in the serum of patients with malignant diseases and lytic bone disease, as well as rheumatoid arthritis (RA). The objective of this study was to measure and compare the concentrations of OPG and RANKL in the synovial fluid (SF) of patients with rheumatoid arthritis, spondyloarthritis (SpA) and osteoarthritis (OA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was an observational and cross-sectional study with 83 patients, 33 with RA, 32 with SpA and 18 with OA, followed up regularly in the outpatient clinics of the Rheumatology Department of the Clinics Hospital of the Ribeir\u00e3o Preto Medical School-USP. All patients were assessed for indications for arthrocentesis by the attending physicians at the time of SF collection and were evaluated for demographic variables and medication use. Disease activity was assessed in individuals with RA and SpA. The quantification of SF OPG and RANKL levels was performed by ELISA, and the correlations of the results with clinical, laboratory and radiological parameters were assessed.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found no statistically significant difference in the RANKL and OPG levels among the groups. Patients with RA showed a positive correlation between the SF cell count and RANKL level (r\u2009=\u20090.59; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and the RANKL\/OPG ratio (r\u2009=\u20090.55; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Patients with OA showed a strong correlation between C-reactive protein (CRP) and the RANKL\/OPG ratio (r\u2009=\u20090.82; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). There was no correlation between the OPG and RANKL levels and markers of inflammatory activity or the disease activity index in patients with RA or SpA.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Within this patient cohort, the RANKL\/OPG ratio was correlated with the SF cell count in patients with RA and with serum CRP in patients with OA, which may suggest a relationship with active inflammation and more destructive joint disease.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-023-00294-3","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:37:17Z","timestamp":1679863037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative study of the synovial levels of RANKL and OPG in rheumatoid arthritis, spondyloarthritis and osteoarthritis"],"prefix":"10.1186","volume":"63","author":[{"given":"Tha\u00edse Oliveira","family":"Quaresma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9rgio Couto Luna","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarc\u00edlia Aparecida","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Louzada-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-6864","authenticated-orcid":false,"given":"Ren\u00ea Donizeti Ribeiro","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"294_CR1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/cells8080818","volume":"8","author":"D Tateiwa","year":"2019","unstructured":"Tateiwa D, Yoshikawa H, Kaito T. Cartilage and bone destruction in arthritis: pathogenesis and treatment strategy: a literature review. Cells. 2019;8:818.","journal-title":"Cells"},{"key":"294_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.0105-2896.2005.00338.x","volume":"208","author":"NC Walsh","year":"2005","unstructured":"Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev. 2005;208:228\u201351.","journal-title":"Immunol Rev"},{"key":"294_CR3","doi-asserted-by":"publisher","first-page":"102400","DOI":"10.1016\/j.jaut.2019.102400","volume":"110","author":"HU Scherer","year":"2020","unstructured":"Scherer HU, H\u00e4upl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020;110:102400.","journal-title":"J Autoimmun"},{"key":"294_CR4","doi-asserted-by":"publisher","first-page":"m4447","DOI":"10.1136\/bmj.m4447","volume":"372","author":"C Ritchlin","year":"2021","unstructured":"Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ. 2021;372:m4447.","journal-title":"BMJ"},{"key":"294_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.joca.2020.10.006","volume":"29","author":"MHJ van den Bosch","year":"2021","unstructured":"van den Bosch MHJ. Osteoarthritis year in review 2020: biology. Osteoarthritis Cartilage. 2021;29:143\u201350.","journal-title":"Osteoarthritis Cartilage"},{"key":"294_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ncprheum0036","volume":"1","author":"G Schett","year":"2005","unstructured":"Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005;1:47\u201354.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"294_CR7","doi-asserted-by":"publisher","first-page":"6324912","DOI":"10.1155\/2021\/6324912","volume":"2021","author":"Y Hu","year":"2021","unstructured":"Hu Y, Wang Y, Chen T, Hao Z, Cai L, Li J. Exosome: function and application in Inflammatory Bone Diseases. Oxid Med Cell Longev. 2021;2021:6324912.","journal-title":"Oxid Med Cell Longev"},{"key":"294_CR8","doi-asserted-by":"publisher","first-page":"16072","DOI":"10.1038\/nrdp.2016.72","volume":"2","author":"J Martel-Pelletier","year":"2016","unstructured":"Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthr Nat Rev Dis Primers. 2016;2:16072.","journal-title":"Osteoarthr Nat Rev Dis Primers"},{"key":"294_CR9","doi-asserted-by":"publisher","first-page":"e141008","DOI":"10.1172\/JCI141008","volume":"131","author":"A Levescot","year":"2021","unstructured":"Levescot A, Chang MH, Schnell J, Nelson-Maney N, Yan J, Mart\u00ednez-Bonet M, et al. IL-1\u03b2-driven osteoclastogenic Tregs accelerate bone erosion in arthritis. J Clin Invest. 2021;131:e141008.","journal-title":"J Clin Invest"},{"key":"294_CR10","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/ijms23052871","volume":"23","author":"K Maeda","year":"2022","unstructured":"Maeda K, Yoshida K, Nishizawa T, Otani K, Yamashita Y, Okabe H, et al. Inflammation and bone metabolism in rheumatoid arthritis: molecular Mechanisms of Joint Destruction and pharmacological treatments. Int J Mol Sci. 2022;23:2871.","journal-title":"Int J Mol Sci"},{"key":"294_CR11","doi-asserted-by":"publisher","first-page":"788680","DOI":"10.3389\/fcell.2021.788680","volume":"9","author":"Y Sun","year":"2021","unstructured":"Sun Y, Li J, Xie X, Gu F, Sui Z, Zhang K, et al. Recent advances in osteoclast biological behavior. Front Cell Dev Biol. 2021;9:788680.","journal-title":"Front Cell Dev Biol"},{"key":"294_CR12","doi-asserted-by":"publisher","first-page":"10683","DOI":"10.3390\/ijms140610683","volume":"14","author":"L Mercatali","year":"2013","unstructured":"Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, et al. RANK\/RANK-L\/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. Int J Mol Sci. 2013;14:10683\u201393.","journal-title":"Int J Mol Sci"},{"key":"294_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-018-1001-2","volume":"38","author":"M Infante","year":"2019","unstructured":"Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A. RANKL\/RANK\/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38:12.","journal-title":"J Exp Clin Cancer Res"},{"key":"294_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/art.23290","volume":"58","author":"B Vandooren","year":"2008","unstructured":"Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK\/RANKL\/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008;58:718\u201329.","journal-title":"Arthritis Rheum"},{"key":"294_CR15","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/art.21896","volume":"54","author":"PP Geusens","year":"2006","unstructured":"Geusens PP, Landew\u00e9 RB, Garnero P, Chen D, Dunstan CR, Lems WF, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006;54:1772\u20137.","journal-title":"Arthritis Rheum"},{"key":"294_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00296-004-0579-1","volume":"26","author":"M Skoumal","year":"2005","unstructured":"Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int. 2005;26:63\u20139.","journal-title":"Rheumatol Int"},{"key":"294_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/rheumatology\/40.6.623","volume":"40","author":"DR Haynes","year":"2001","unstructured":"Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology. 2001;40:623\u201330.","journal-title":"Rheumatology"},{"key":"294_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/rheumatology\/keg047","volume":"42","author":"DR Haynes","year":"2003","unstructured":"Haynes DR, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology. 2003;42:123\u201334.","journal-title":"Rheumatology"},{"key":"294_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.clinbiochem.2008.02.011","volume":"41","author":"A Pilichou","year":"2008","unstructured":"Pilichou A, Papassotiriou I, Michalakakou K, Fessatou S, Fandridis E, Papachristou G, et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem. 2008;41:746\u20139.","journal-title":"Clin Biochem"},{"issue":"Suppl 6","key":"294_CR20","doi-asserted-by":"publisher","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay J, Upchurch KS. ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51(Suppl 6):vi5\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"294_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-016-3261-6","volume":"35","author":"N Akkoc","year":"2016","unstructured":"Akkoc N, Khan MA. ASAS classification criteria for axial spondyloarthritis: time to modify. Clin Rheumatol. 2016;35:1415\u201323.","journal-title":"Clin Rheumatol"},{"key":"294_CR22","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27:1578\u201389.","journal-title":"Osteoarthritis Cartilage"},{"key":"294_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","volume":"71","author":"BR England","year":"2019","unstructured":"England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, et al. 2019 update of the American college of rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res. 2019;71:1540\u201355.","journal-title":"Arthritis Care Res"},{"key":"294_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Assessment of SpondyloArthritis international society. Ankylosing Spondylitis Disease Activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis"},{"key":"294_CR25","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1136\/ard.2010.147520","volume":"70","author":"D Schiphof","year":"2011","unstructured":"Schiphof D, de Klerk BM, Kerkhof HJ, Hofman A, Koes BW, Boers M, et al. Impact of different descriptions of the Kellgren and Lawrence classification criteria on the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2011;70:1422\u20137.","journal-title":"Ann Rheum Dis"},{"key":"294_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00296-011-1831-0","volume":"32","author":"AS Ellabban","year":"2012","unstructured":"Ellabban AS, Kamel SR, Ahmed SS, Osman AM. Receptor activator of nuclear factor kappa B ligand serum and synovial fluid level. A comparative study between rheumatoid arthritis and osteoarthritis. Rheumatol Int. 2012;32:1589\u201396.","journal-title":"Rheumatol Int"},{"key":"294_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/46303","volume":"402","author":"YY Kong","year":"1999","unstructured":"Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304\u20139.","journal-title":"Nature"},{"key":"294_CR28","first-page":"185","volume":"23","author":"JE Fonseca","year":"2005","unstructured":"Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canh\u00e3o H, Resende C, et al. Inflammatory cell infiltrate and RANKL\/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol. 2005;23:185\u201392.","journal-title":"Clin Exp Rheumatol"},{"key":"294_CR29","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/ar2137","volume":"9","author":"PE Poubelle","year":"2007","unstructured":"Poubelle PE, Chakravarti A, Fernandes MJ, Doiron K, Marceau AA. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res Ther. 2007;9:R25.","journal-title":"Arthritis Res Ther"},{"key":"294_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/36593","volume":"390","author":"DM Anderson","year":"1997","unstructured":"Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175\u20139.","journal-title":"Nature"},{"key":"294_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13018-021-02271-2","volume":"16","author":"Y Mori","year":"2021","unstructured":"Mori Y, Izumiyama T, Kurishima H, Kamimura M, Baba K, Mori N, et al. Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies. J Orthop Surg Res. 2021;16:107.","journal-title":"J Orthop Surg Res"},{"key":"294_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/14397595.2016.1232776","volume":"27","author":"H Kinoshita","year":"2017","unstructured":"Kinoshita H, Miyakoshi N, Kashiwagura T, Kasukawa Y, Sugimura Y, Shimada Y. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. Mod Rheumatol. 2017;27:582\u20136.","journal-title":"Mod Rheumatol"},{"key":"294_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. 2019;78:899\u2013907.","journal-title":"Ann Rheum Dis"},{"key":"294_CR34","doi-asserted-by":"publisher","first-page":"799575","DOI":"10.3389\/fimmu.2021.799575","volume":"12","author":"Q Hu","year":"2022","unstructured":"Hu Q, Zhong X, Tian H, Liao P. The efficacy of Denosumab in patients with rheumatoid arthritis: a systematic review and pooled analysis of Randomized or Matched Data. Front Immunol. 2022;12:799575.","journal-title":"Front Immunol"},{"key":"294_CR35","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1001\/jama.282.22.2131","volume":"282","author":"M Visser","year":"1999","unstructured":"Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131\u20135.","journal-title":"JAMA"},{"key":"294_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diabet.2011.11.006","volume":"38","author":"MC Calle","year":"2012","unstructured":"Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab. 2012;38:183\u201391.","journal-title":"Diabetes Metab"},{"issue":"5544","key":"294_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/bmj.2.5544.85","volume":"2","author":"LE B\u00f6ttiger","year":"1967","unstructured":"B\u00f6ttiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. Br Med J. 1967;2(5544):85\u20137.","journal-title":"Br Med J"},{"issue":"Suppl 2","key":"294_CR38","doi-asserted-by":"publisher","first-page":"ii56","DOI":"10.1093\/rheumatology\/kew345","volume":"55","author":"SR Goldring","year":"2016","unstructured":"Goldring SR. Differential mechanisms of de-regulated bone formation in rheumatoid arthritis and spondyloarthritis. Rheumatology. 2016;55(Suppl 2):ii56\u2013ii60.","journal-title":"Rheumatology"},{"key":"294_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1080\/08820139.2019.1567531","volume":"48","author":"M Chen","year":"2019","unstructured":"Chen M, Hu X, Wu M, Yang J, Han R, Ma Y, et al. Serum levels of OPG, RANKL, and RANKL\/OPG ratio in patients with Ankylosing Spondylitis: a systematic review and Meta-analysis. Immunol Invest. 2019;48:490\u2013504.","journal-title":"Immunol Invest"},{"key":"294_CR40","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.3390\/jcm10132905","volume":"10","author":"A Jura-P\u00f3\u0142torak","year":"2021","unstructured":"Jura-P\u00f3\u0142torak A, Szeremeta A, Olczyk K, Zo\u0144-Giebel A, Komosi\u0144ska-Vassev K. Bone metabolism and RANKL\/OPG ratio in rheumatoid arthritis women treated with TNF-\u03b1 inhibitors. J Clin Med. 2021;10:2905.","journal-title":"J Clin Med"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00294-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-023-00294-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-023-00294-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:37:24Z","timestamp":1679863044000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-023-00294-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["294"],"URL":"https:\/\/doi.org\/10.1186\/s42358-023-00294-3","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee approved the study (CAAE: 59784122.8.0000.5440). All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}